Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study.
Claudio Maurizio PacellaGianluigi PatelliGennaro IapiccaGuglielmo ManentiTommaso PerrettaColleen P RyanRenato EspositoGiovanni MauriPublished in: Prostate cancer and prostatic diseases (2019)
SoracteLite™ TPLA allows significant improvement of IPSS, Qol, Qmax, PVR, and reduction of prostatic volume at 6 and 12 months.